Clinical data | |
---|---|
Trade names | Levo-Dromoran |
Other names | Ro 1-5431[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682020 |
Routes of administration | Oral, intravenous, subcutaneous, intramuscular |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 70% (oral); 100% (IV) |
Protein binding | 40% |
Metabolism | Hepatic |
Elimination half-life | 11–16 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.912 |
Chemical and physical data | |
Formula | C17H23NO |
Molar mass | 257.377 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Levorphanol (brand name Levo-Dromoran) is an opioid medication used to treat moderate to severe pain.[1][3][4] It is the levorotatory enantiomer of the compound racemorphan. Its dextrorotatory counterpart is dextrorphan.
It was first described in Germany in 1946.[5] The drug has been in medical use in the United States since 1953.[6]